Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + cisplatin is a chemotherapy combination regimen used to treat several types of cancer, including non-small cell lung cancer, biliary tract cancer, bladder cancer, cervical cancer, malignant mesothelioma, ovarian cancer, and pancreatic cancer. Gemcitabine is an antimetabolite that mimics nucleosides and disrupts DNA synthesis by being incorporated into DNA strands during replication, leading to masked chain termination and inhibition of further DNA synthesis. It also inhibits ribonucleotide reductase via its diphosphate form. Cisplatin is an alkylating agent that forms crosslinks in DNA strands and prevents cell division by causing irreparable damage to the genetic material. The combination exploits different mechanisms to destroy rapidly dividing cells more effectively than either drug alone.
- Brand names
- GemCisGC
- Other names
- GEMCITABINE-CISPLATINCISplatin-Gemcitabine
02
Targets
POLA1 (DNA polymerase alpha)RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin.